Table S1-S3; Figure S1-S13 from BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer
Year: 2023
Type: other
Abstract: Supplementary Table S1. Detailed information about the antibodies used. Supplementary Table S2. Proportions of listed immune cell subsets in the tumor microenvironment of NSCLC GEMs were evaluated by FACS utilizing indicated lineage markers and proteins. Supplementary Table S3. Tumor cells from treated KP mice were subjected to RNA-sequencing. Supplementary Figure S1. Kinetics of tumor growth in KP mice treated with anti-PD-1. Supplementary Figure S2. Immune cell proportions in the tumors of treated KP mice. Supplementary Figure S3. PD-1 is prominently expressed on tumor-infiltrating T cells in GEMM of NSCLC. Supplementary Figure S4. Decreased expression of PD-1 and CTLA-4 on tumor-infiltrating CD4+ T cells under JQ1 treatment. Supplementary Figure S5. Increased expression of MHC class I on tumor-infiltrating tumor-associated macrophages (TAMs). Supplementary Figure S6. Combination of JQ1 and PD-1 blockade evokes unique genomic genomic changes in tumors of treated KP mice. Supplementary Figure S7. Overall survival of tumor-bearing nude mice treated with JQ1 or anti-PD-1. Supplementary Figure S8. JQ1 and/or anti-PD-1 treatment facilitated enhanced effector function of tumor-infiltrating CD8+ T cells. Supplementary Figure S9. Combination of JQ1 and α-PD-1 did not have substantial deleterious effects on tumor-associated T cells. Supplementary Figure S10. Tumor-infiltrating KLRG1+ CD4+Foxp3+ Tregs exhibit a highly activated profile but resemble natural peripheral Tregs. Supplementary Figure S11. Tumor-infiltrating KLRG1+ CD4+Foxp3+ Tregs are not derived from CD4+CD25- cells. Supplementary Figure S12. Tumor-associated KLRG1+ Tregs express higher CTLA-4 and demonstrate enhanced suppressive function. Supplementary Figure S13. Decreased expression of Treg signature proteins and Bcl-2 on tumor-infiltrating KLRG1+ Treg subset under JQ1 treatment.
Authors: Dennis O. Adeegbe, Shengwu Liu, Maureen M. Hattersley, Michaela Bowden, Chensheng W. Zhou, Shuai Li, Raven Vlahos, Michael Grondine, Igor Dolgalev, Elena V. Ivanova, Max M. Quinn, Peng Gao, Peter S. Hammerman, James E. Bradner, J. Alan Diehl, Anil K. Rustgi, Adam J. Bass, Aristotelis Tsirigos, Gordon J. Freeman, Huawei Chen, Kwok-Kin Wong
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362640213